[Report of the 55th meeting of the American Academy of Neurology. Honolulu, March 29-April 6, 2003].
Becker
H
H
Chochon
F
F
de Toffol
B
B
Defebvre
L
L
Léger
J M
JM
Pierrot-Deseilligny
C
C
Sellal
F
F
D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001720:Birth Injuries; D002986:Clinical Trials as Topic; D003704:Dementia / Q000145:classification / Q000209:etiology / Q000628:therapy; D004200:Diseases in Twins; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D005260:Female; D006261:Headache / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000145:classification / Q000188:drug therapy / Q000628:therapy; D009462:Neurology; D009471:Neuromyelitis Optica / Q000175:diagnosis; D010300:Parkinson Disease / Q000188:drug therapy / Q000209:etiology; D010523:Peripheral Nervous System Diseases / Q000145:classification / Q000175:diagnosis / Q000628:therapy; D014202:Tremor / Q000188:drug therapy; D014652:Vascular Diseases / Q000628:therapy
D000927:Anticonvulsants; D000978:Antiparkinson Agents